Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 2, 1996, Pages 147-154

  Boddy, Alan V ^a   Yule, S Murray ^a   Wyllie, Ruth ^a   Price, Lisa ^a   Pearson, Andrew D J ^a   Idle, Jeffrey R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

ifosfamide; metabolism; pediatrics; pharmacokinetics; variability

Indexed keywords

ALPHA TOCOPHEROL; BISACODYL; CARBAMAZEPINE; CODEINE; COTRIMOXAZOLE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; FLUCLOXACILLIN; FUROSEMIDE; IFOSFAMIDE; IMIPENEM; LACTULOSE; METOCLOPRAMIDE; MICONAZOLE; NORETHISTERONE; NYSTATIN; ONDANSETRON; PARACETAMOL; POTASSIUM CHLORIDE; TEICOPLANIN; VINCRISTINE;

ADOLESCENT; ARTICLE; BLOOD LEVEL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; URINE LEVEL;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IFOSFAMIDE; INFANT; INFUSION PUMPS; MALE; REPRODUCIBILITY OF RESULTS;

EID: 0030000708     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050463     Document Type: Article

References (29)

1. Boddy AV, and Idle JR (1992) Combined thin-layer chromatography-photography-densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma. J Chromatogr Biomed Appl 575:137.
2. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, and Idle JR (1993) Pharmacokinetics and metabolism in children of ifosfamide administered as a continuous infusion. Cancer Res 53:3758.
3. Boddy AV, Cole M, Pearson ADJ, Idle JR (1995) The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 36:53.
4. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR (1995) Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 31A:985.
5. Boos J, Welslau U, Ritter J, Blaschke G, Schellong G (1991) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28:455
6. Chang TKH, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629
7. Colquhoun MC, Daly M, Stewart P, Beeley L (1987) Interaction between warfarin and miconazole oral gel. Lancet 1:695
8. Guard V, Malet-Martino MC, Martino R, Niemeyer U, Forni M de (1993) Ifosfamide metabolism from phosphorus-31 magnetic resonance spectroscopy analysis of patients' urine. Proc Am Assoc Cancer Res 34:268.
9. Gillard V, Malet-Martino MC, Forni M de, Niemeyer U, Ader JC, Martino R (1993) Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy. Cancer Chemother Pharmacol 31:387
10. Harten J van, Duchier J, Devissaguet JP, Bemmel P van, Vries MH de, Raghoebar M (1993) Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet 24: 177
11. Hartley JM, Hansen L, Harland SJ, Nicholson PW, Pasini F, Souhami RL (1994) Metabolism of ifosfamide during a 3 day infusion. Br J Cancer 69:931.
12. Johnson PJ, Dobbs N, Kalayci C, Aldous MC, Harper P, Metivier EM, Williams R (1992) Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 65:751
13. Kurowski V, Wagner T (1993) Comparative pharmacokientics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde and 2-and 3-dechloroethylifosfamidein patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36
14. Laplanche R, Fertil B, Nuesch E, Jais J-P, Niederberger W, Steimer J-L (1991) Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine. Clin Pharmacol Ther 50:39
15. Lear L, Nation RL, Stupans I (1992) Effects of cyclophosphamide and adriamycin on rat hepatic-microsomal glucuronidation and lipid-peroxidation Biochem Pharmacol 44:747
16. Leblanc BA, Waxman DJ (1990) Mechanisms of cyclophosphamide action on hepatic P-450 expression. Cancer Res 50:5720
17. Lind MJ, Roberts HL, Thatcher N, Idle JR (1990) The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 26:105
18. MacPhee GJA, Thompson GG, Scobie G, Agnew E, Park BK, Murray T, McColl KEL, Brodie MJ (1984) Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol 18:411
19. Moore MJ, Ehrlichman C, Thiessen JJ, Bunting PS, Hardy R, Kerr I, Soldin S (1994) Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother Pharmacol 33:472
20. Morgan LR, Posey LE, Rainey J, Beickers J, Ryan D, Vial R, Hull E (1981) Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep 65:693
21. Mouridsen HT, Faber O, Skovsted L (1976) The metabolism of cyclophosphamide: dose-dependency and the effect of long-term treatment with cyclophosphamide. Cancer 37:665
22. O'Brien S, Benvenuto JA, Estey E, Beran M, Felder TB, Keating M (1991) Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. Cancer Res 31:935
23. Pratt CB (1992) Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States. Semin Oncol 19:43.
24. Sladek N (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37:301
25. Stewart CF, Arbuck SG, Fleming RA, Evans WE (1990) Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 8: 1874
26. Sutherland L, Ebner T, Burchell B (1993) The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 45:295
27. Walker D, Flinois J-P, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH, Idle JR (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47:1157
28. Wang JH, Chan KK (1994) Identification of ifosfamide (IF) metabolites in rat urine. Proc Am Assoc Cancer Res 35:300
29. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Pearson ADJ, Idle JR (1994) Cyclophosphamide pharmacokinetics in children; sources of inter-patient variation. Proc Am Assoc Cancer Res 35:433